 Connection
Petter Bjornstad to Glucagon-Like Peptide 1
This is a "connection" page, showing publications Petter Bjornstad has written about Glucagon-Like Peptide 1.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.318 |
|
|
|
-
Tommerdahl KL, Kendrick J, Bjornstad P. The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial. Clin J Am Soc Nephrol. 2022 06; 17(6):905-907.
Score: 0.162
-
Dobbs TJ, Pyle L, Moore JM, Garrish J, Behn CD, Weissenkampen D, Baumgartner AD, Gross S, Schutte G, Birznieks C, Melena I, Remmers L, Driscoll L, Cree MG, Kelsey MM, Shah AS, Inge TH, Bjornstad P, Nadeau KJ. Impact of Vertical Sleeve Gastrectomy in Youth-Onset Type 2 Diabetes: Changes in Glycemia, Insulin Sensitivity, and Secretion. Obesity (Silver Spring). 2026 Jun; 34 Suppl 1:121-133.
Score: 0.053
-
Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, Hodgin JB, Schytz PA, Tuttle KR, Kretzler M. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2026 01; 109(1):6-16.
Score: 0.052
-
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|